{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T22:09:12Z","timestamp":1794262152759,"version":"4.9.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,10,27]],"date-time":"2020-10-27T00:00:00Z","timestamp":1603756800000},"content-version":"vor","delay-in-days":26,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000062","name":"U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["RC2-DK118620"],"award-info":[{"award-number":["RC2-DK118620"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["R01-DK099110"],"award-info":[{"award-number":["R01-DK099110"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["R01-DK55758"],"award-info":[{"award-number":["R01-DK55758"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["P01-DK088761"],"award-info":[{"award-number":["P01-DK088761"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"name":"U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases"},{"name":"U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases"},{"name":"U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases"},{"DOI":"10.13039\/100000049","name":"U.S. Department of Health & Human Services | NIH | National Institute on Aging","doi-asserted-by":"publisher","award":["P01-AG051459"],"award-info":[{"award-number":["P01-AG051459"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["2017R1C1B1008424"],"award-info":[{"award-number":["2017R1C1B1008424"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["2020R1A2C4001503"],"award-info":[{"award-number":["2020R1A2C4001503"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["2018R1A5A1024340"],"award-info":[{"award-number":["2018R1A5A1024340"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["2018R1A2B6003878"],"award-info":[{"award-number":["2018R1A2B6003878"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["2017M3A9C4065956"],"award-info":[{"award-number":["2017M3A9C4065956"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Exp Mol Med"],"published-print":{"date-parts":[[2020,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Non-alcoholic fatty liver disease (NAFLD) is the most common liver disease and can lead to multiple complications, including non-alcoholic steatohepatitis (NASH), cirrhosis, and hepatocellular carcinoma. The fibrotic liver is characterized by the pathological accumulation of extracellular matrix (ECM) proteins. Type VI collagen alpha3 (Col6a3) is a biomarker of hepatic fibrosis, and its cleaved form, endotrophin (ETP), plays a critical role in adipose tissue dysfunction, insulin resistance, and breast cancer development. Here, we studied the effects of the Col6a3-derived peptide ETP on the progression of chronic liver diseases, such as NASH and liver cancer. We used a doxycycline (Dox)-inducible liver-specific ETP-overexpressing mouse model on a NAFLD-prone (liver-specific SREBP1a transgenic) background. For this, we evaluated the consequences of local ETP expression in the liver and its effect on hepatic inflammation, fibrosis, and insulin resistance. Accumulation of ETP in the liver induced hepatic inflammation and the development of fibrosis with associated insulin resistance. Surprisingly, ETP overexpression also led to the emergence of liver cancer within 10 months in the SREBP1a transgenic background. Our data revealed that ETP can act as a \u201csecond hit\u201d during the progression of NAFLD and can play an important role in the development of NASH and hepatocellular carcinoma (HCC). These observations firmly link elevated levels of ETP to chronic liver disease.<\/jats:p>","DOI":"10.1038\/s12276-020-00520-8","type":"journal-article","created":{"date-parts":[[2020,10,27]],"date-time":"2020-10-27T10:04:14Z","timestamp":1603793054000},"page":"1766-1776","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":45,"title":["The impact of endotrophin on the progression of chronic liver disease"],"prefix":"10.1038","volume":"52","author":[{"given":"Min","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changhu","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dae Yun","family":"Seo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyojung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay D.","family":"Horton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3705-4769","authenticated-orcid":false,"given":"Jiyoung","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0680-3392","authenticated-orcid":false,"given":"Philipp E.","family":"Scherer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,27]]},"reference":[{"key":"520_CR1","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.2337\/diabetes.50.8.1844","volume":"50","author":"G Marchesini","year":"2001","unstructured":"Marchesini, G. et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 50, 1844\u20131850 (2001).","journal-title":"Diabetes"},{"key":"520_CR2","first-page":"E1","volume":"389","author":"T Lallukka","year":"2017","unstructured":"Lallukka, T., Millear, A., Pain, A., Cortinovis, M. & Giussani, G. GBD 2015 Mortality and Causes of Death Collaborators. Global, regional, and national life expectancy, all-cause mortality, and cause-specifi c mortality for 249 causes of death, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet 389, E1 (2017).","journal-title":"Lancet"},{"key":"520_CR3","doi-asserted-by":"publisher","unstructured":"Chen, P. et al. Dexmedetomidine promotes the progression of hepatocellular carcinoma through hepatic stellate cell activation. Exp. Mol. Med. https:\/\/doi.org\/10.1038\/s12276-020-0461-6 (2020).","DOI":"10.1038\/s12276-020-0461-6"},{"key":"520_CR4","doi-asserted-by":"publisher","unstructured":"Koo, S. Y., Park, E. J., & Lee, C. W. Immunological distinctions between nonalcoholic steatohepatitis and hepatocellular carcinoma. Exp. Mol. Med. https:\/\/doi.org\/10.1038\/s12276-020-0480-3 (2020).","DOI":"10.1038\/s12276-020-0480-3"},{"key":"520_CR5","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1056\/NEJM199306243282501","volume":"328","author":"H Tsukuma","year":"1993","unstructured":"Tsukuma, H. et al. Risk-factors for hepatocellular-carcinoma among patients with chronic liver-disease. N. Engl. J. Med. 328, 1797\u20131801 (1993).","journal-title":"N. Engl. J. Med."},{"key":"520_CR6","doi-asserted-by":"publisher","first-page":"255","DOI":"10.3748\/wjg.v11.i2.255","volume":"11","author":"H Sakugawa","year":"2005","unstructured":"Sakugawa, H. et al. Clinical usefulness of biochemical markers of liver fibrosis in patients with nonalcoholic fatty liver disease. World J. Gastroenterol. 11, 255\u2013259 (2005).","journal-title":"World J. Gastroenterol."},{"key":"520_CR7","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1056\/NEJM199705293362217","volume":"336","author":"B Gerling","year":"1997","unstructured":"Gerling, B., Becker, M., Staab, D. & Schuppan, D. Prediction of liver fibrosis according to serum collagen VI level in children with cystic fibrosis. N. Engl. J. Med. 336, 1611\u20131612 (1997).","journal-title":"N. Engl. J. Med."},{"key":"520_CR8","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1002\/oby.20758","volume":"22","author":"SN Dankel","year":"2014","unstructured":"Dankel, S. N. et al. COL6A3 expression in adipocytes associates with insulin resistance and depends on PPAR gamma and adipocyte Size. Obesity 22, 1807\u20131813 (2014).","journal-title":"Obesity"},{"key":"520_CR9","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1002\/oby.21565","volume":"24","author":"S Gesta","year":"2016","unstructured":"Gesta, S. et al. Reduced expression of collagen VI alpha 3 (COL6A3) confers resistance to inflammation-induced MCP1 expression in adipocytes. Obesity (Silver Spring) 24, 1695\u20131703 (2016).","journal-title":"Obesity (Silver Spring)"},{"key":"520_CR10","first-page":"2527","volume":"39","author":"W Liu","year":"2018","unstructured":"Liu, W., Li, L., Ye, H., Tao, H. & He, H. Role of COL6A3 in colorectal cancer. Oncol. Rep. 39, 2527\u20132536 (2018).","journal-title":"Oncol. Rep."},{"key":"520_CR11","doi-asserted-by":"publisher","first-page":"4243","DOI":"10.1172\/JCI63930","volume":"122","author":"J Park","year":"2012","unstructured":"Park, J. & Scherer, P. E. Adipocyte-derived endotrophin promotes malignant tumor progression. J. Clin. Invest. 122, 4243\u20134256 (2012).","journal-title":"J. Clin. Invest"},{"key":"520_CR12","doi-asserted-by":"publisher","unstructured":"Sun, K. et al. Endotrophin triggers adipose tissue fibrosis and metabolic dysfunction. Nat. Commun. 5, https:\/\/doi.org\/10.1038\/Ncomms4485 (2014).","DOI":"10.1038\/Ncomms4485"},{"key":"520_CR13","doi-asserted-by":"publisher","unstructured":"Bu, D. W. et al. Human endotrophin as a driver of malignant tumor growth. JcI Insight 4, https:\/\/doi.org\/10.1172\/jci.insight.125094 (2019).","DOI":"10.1172\/jci.insight.125094"},{"key":"520_CR14","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1002\/path.5172","volume":"247","author":"C Lee","year":"2019","unstructured":"Lee, C. et al. COL6A3-derived endotrophin links reciprocal interactions among hepatic cells in the pathology of chronic liver disease. J. Pathol. 247, 99\u2013109 (2019).","journal-title":"J. Pathol."},{"key":"520_CR15","doi-asserted-by":"publisher","first-page":"e0175200","DOI":"10.1371\/journal.pone.0175200","volume":"12","author":"A Fenton","year":"2017","unstructured":"Fenton, A. et al. Serum endotrophin, a type VI collagen cleavage product, is associated with increased mortality in chronic kidney disease. PLoS ONE 12, e0175200 (2017).","journal-title":"PLoS ONE"},{"key":"520_CR16","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1007\/s00125-016-4094-1","volume":"60","author":"MA Karsdal","year":"2017","unstructured":"Karsdal, M. A. et al. Serum endotrophin identifies optimal responders to PPARgamma agonists in type 2 diabetes. Diabetologia 60, 50\u201359 (2017).","journal-title":"Diabetologia"},{"key":"520_CR17","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1002\/emmm.201202006","volume":"5","author":"J Park","year":"2013","unstructured":"Park, J., Morley, T. S. & Scherer, P. E. Inhibition of endotrophin, a cleavage product of collagen VI, confers cisplatin sensitivity to tumours. Embo. Mol. Med. 5, 935\u2013948 (2013).","journal-title":"Embo. Mol. Med."},{"key":"520_CR18","doi-asserted-by":"publisher","first-page":"36652","DOI":"10.1074\/jbc.M306540200","volume":"278","author":"JD Horton","year":"2003","unstructured":"Horton, J. D., Shimomura, I., Ikemoto, S., Bashmakov, Y. & Hammer, R. E. Overexpression of sterol regulatory element-binding protein-1a in mouse adipose tissue produces adipocyte hypertrophy, increased fatty acid secretion, and fatty liver. J. Biol. Chem. 278, 36652\u201336660 (2003).","journal-title":"J. Biol. Chem."},{"key":"520_CR19","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1172\/JCI118951","volume":"98","author":"H Shimano","year":"1996","unstructured":"Shimano, H. et al. Overproduction of cholesterol and fatty acids causes massive liver enlargement in transgenic mice expressing truncated SREBP-1a. J. Clin. Invest. 98, 1575\u20131584 (1996).","journal-title":"J. Clin. Invest"},{"key":"520_CR20","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.bbadis.2004.11.006","volume":"1740","author":"A Takahashi","year":"2005","unstructured":"Takahashi, A. et al. Transgenic mice overexpressing SREBP-1a under the control of the PEPCK promoter exhibit insulin resistance, but not diabetes. Bba-Mol. Basis Dis. 1740, 427\u2013433 (2005).","journal-title":"Bba-Mol. Basis Dis."},{"key":"520_CR21","doi-asserted-by":"publisher","first-page":"99","DOI":"10.15430\/JCP.2018.23.2.99","volume":"23","author":"J Lee","year":"2018","unstructured":"Lee, J., Kim, E., Kim, Y. & Yoo, S. H. Leucrose, a sucrose isomer, suppresses hepatic fat accumulation by regulating hepatic lipogenesis and fat oxidation in high-fat diet-induced obese mice. J. Cancer Prev. 23, 99\u2013106 (2018).","journal-title":"J. Cancer Prev."},{"key":"520_CR22","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.cmet.2015.06.007","volume":"22","author":"JY Xia","year":"2015","unstructured":"Xia, J. Y. et al. Targeted induction of ceramide degradation leads to improved systemic metabolism and reduced hepatic steatosis. Cell Metab. 22, 266\u2013278 (2015).","journal-title":"Cell Metab."},{"key":"520_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.molmet.2018.02.013","volume":"11","author":"Y Deng","year":"2018","unstructured":"Deng, Y. et al. Adipocyte Xbp1s overexpression drives uridine production and reduces obesity. Mol. Metab. 11, 1\u201317 (2018).","journal-title":"Mol. Metab."},{"key":"520_CR24","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.2337\/db16-1081","volume":"66","author":"J Park","year":"2017","unstructured":"Park, J. et al. VEGF-A-expressing adipose tissue shows rapid beiging and enhanced survival after transplantation and confers IL-4-independent metabolic improvements. Diabetes 66, 1479\u20131490 (2017).","journal-title":"Diabetes"},{"key":"520_CR25","doi-asserted-by":"publisher","first-page":"2308","DOI":"10.1210\/en.2017-03179","volume":"159","author":"H Ohno","year":"2018","unstructured":"Ohno, H. et al. Transgenic mice overexpressing SREBP-1a in male ob\/ob mice exhibit lipodystrophy and exacerbate insulin resistance. Endocrinology 159, 2308\u20132323 (2018).","journal-title":"Endocrinology"},{"key":"520_CR26","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1172\/JCI119248","volume":"99","author":"H Shimano","year":"1997","unstructured":"Shimano, H. et al. Isoform 1c of sterol regulatory element binding protein is less active than isoform 1a in livers of transgenic mice and in cultured cells. J. Clin. Invest. 99, 846\u2013854 (1997).","journal-title":"J. Clin. Invest"},{"key":"520_CR27","doi-asserted-by":"publisher","unstructured":"Solinas, G. & Becattini, B. JNK at the crossroad of obesity, insulin resistance, and cell stress response. Mol. Metab. 6, https:\/\/doi.org\/10.1016\/j.molmet.2016.12.001 (2017).","DOI":"10.1016\/j.molmet.2016.12.001"},{"key":"520_CR28","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1038\/nbt.1526","volume":"27","author":"VW Keng","year":"2009","unstructured":"Keng, V. W. et al. A conditional transposon-based insertional mutagenesis screen for genes associated with mouse hepatocellular carcinoma. Nat. Biotechnol. 27, 264\u2013274 (2009).","journal-title":"Nat. Biotechnol."},{"key":"520_CR29","doi-asserted-by":"publisher","first-page":"S96","DOI":"10.1111\/j.1440-1746.2006.04665.x","volume":"22","author":"S Watanabe","year":"2007","unstructured":"Watanabe, S. et al. Non-alcoholic steatohepatitis and hepatocellular carcinoma: lessons from hepatocyte-specific phosphatase and tensin homolog (PTEN)-deficient mice. J. Gastroenterol. Hepatol. 22, S96\u2013S100 (2007).","journal-title":"J. Gastroenterol. Hepatol."},{"key":"520_CR30","doi-asserted-by":"publisher","unstructured":"Liu, Y. Z. et al. CRISPR\/Cas9-mediated p53 and Pten dual mutation accelerates hepatocarcinogenesis in adult hepatitis B virus transgenic mice. Sci. Rep. 7, https:\/\/doi.org\/10.1038\/s41598-017-03070-8 (2017).","DOI":"10.1038\/s41598-017-03070-8"},{"key":"520_CR31","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1038\/cmi.2014.2","volume":"11","author":"R Xu","year":"2014","unstructured":"Xu, R., Huang, H., Zhang, Z. & Wang, F. S. The role of neutrophils in the development of liver diseases. Cell Mol. Immunol. 11, 224\u2013231 (2014).","journal-title":"Cell Mol. Immunol."},{"key":"520_CR32","doi-asserted-by":"publisher","unstructured":"Asimakopoulou, A., Weiskirchen, S. & Weiskirchen, R. Lipocalin 2 (LCN2) Expression in Hepatic Malfunction and Therapy. Front. Physiol. 7, https:\/\/doi.org\/10.3389\/fphys.2016.00430 (2016).","DOI":"10.3389\/fphys.2016.00430"},{"key":"520_CR33","doi-asserted-by":"publisher","unstructured":"Siegmund, S. V. et al. Serum Amyloid A Induces Inflammation, Proliferation and Cell Death in Activated Hepatic Stellate Cells. PLos ONE 11, https:\/\/doi.org\/10.1371\/journal.pone.0150893 (2016).","DOI":"10.1371\/journal.pone.0150893"},{"key":"520_CR34","first-page":"13","volume":"17","author":"D Anthony","year":"2012","unstructured":"Anthony, D., Seow, H. J., Vlahos, R., Anderson, G. P. & Bozinovski, S. Serum amyloid a (Saa) induces Il-17a dependent neutrophilic inflammation in the lung. Respirology 17, 13\u201313 (2012).","journal-title":"Respirology"},{"key":"520_CR35","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1172\/JCI121087","volume":"129","author":"SA Christenson","year":"2019","unstructured":"Christenson, S. A. et al. An airway epithelial IL-17A response signature identifies a steroid-unresponsive COPD patient subgroup. J. Clin. Invest. 129, 169\u2013181 (2019).","journal-title":"J. Clin. Invest."},{"key":"520_CR36","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1002\/mc.2940020610","volume":"2","author":"TA Dragani","year":"1989","unstructured":"Dragani, T. A., Manenti, G., Sacchi, M. R. M., Colombo, B. M. & Dellaporta, G. Major urinary protein as a negative tumor-marker in mouse hepatocarcinogenesis. Mol. Carcinog. 2, 355\u2013360 (1989).","journal-title":"Mol. Carcinog."}],"container-title":["Experimental &amp; Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s12276-020-00520-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s12276-020-00520-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s12276-020-00520-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,26]],"date-time":"2021-10-26T23:07:44Z","timestamp":1635289664000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s12276-020-00520-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":36,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["520"],"URL":"https:\/\/doi.org\/10.1038\/s12276-020-00520-8","relation":{},"ISSN":["1226-3613","2092-6413"],"issn-type":[{"value":"1226-3613","type":"print"},{"value":"2092-6413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"10 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}